Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
© 2021. The Author(s), under exclusive licence to Springer Nature Limited..
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay that detects IgG antibodies to SARS-CoV-2 spike protein, we determined serum antibody levels prior to immunization and 12-21 and 14-21 days following the first and second vaccinations, respectively, with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) among 103 MM patients (96 and 7 with active and smoldering disease, respectively). We stratified patients into clinically relevant responders (>250 IU/mL), partial responders (50-250 IU/mL, which was above pre-COVID-19 background), and nonresponders (<50 IU/mL). Smoldering MM patients responded better than those with active disease. Only 45% of active MM patients developed an adequate response, while 22% had a partial response. Lower spike antibody levels were associated with older age, impaired renal function, low lymphocyte counts, reduced uninvolved immunoglobulin levels, > second line of treatment, and among those not in complete remission. Patients who received mRNA-1273 vaccine had higher anti-spike antibody levels than those who were vaccinated with BNT162b2. Thus, most MM patients have impaired responses to mRNA vaccination against COVID-19, and specific clinical and myeloma-related characteristics predict vaccine responsiveness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Leukemia - 35(2021), 12 vom: 29. Dez., Seite 3534-3541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stampfer, Samuel D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 17.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-021-01354-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328710660 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328710660 | ||
| 003 | DE-627 | ||
| 005 | 20231225203524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-021-01354-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328710660 | ||
| 035 | |a (NLM)34326466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stampfer, Samuel D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to mRNA vaccination for COVID-19 among patients with multiple myeloma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 17.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay that detects IgG antibodies to SARS-CoV-2 spike protein, we determined serum antibody levels prior to immunization and 12-21 and 14-21 days following the first and second vaccinations, respectively, with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech) among 103 MM patients (96 and 7 with active and smoldering disease, respectively). We stratified patients into clinically relevant responders (>250 IU/mL), partial responders (50-250 IU/mL, which was above pre-COVID-19 background), and nonresponders (<50 IU/mL). Smoldering MM patients responded better than those with active disease. Only 45% of active MM patients developed an adequate response, while 22% had a partial response. Lower spike antibody levels were associated with older age, impaired renal function, low lymphocyte counts, reduced uninvolved immunoglobulin levels, > second line of treatment, and among those not in complete remission. Patients who received mRNA-1273 vaccine had higher anti-spike antibody levels than those who were vaccinated with BNT162b2. Thus, most MM patients have impaired responses to mRNA vaccination against COVID-19, and specific clinical and myeloma-related characteristics predict vaccine responsiveness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Goldwater, Marissa-Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Jew, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Regidor, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Daniely, David |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Eddie |e verfasserin |4 aut | |
| 700 | 1 | |a Aquino, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Eshaghian, Shahrooz |e verfasserin |4 aut | |
| 700 | 1 | |a Preugschat, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Feinstein, Aaron J |e verfasserin |4 aut | |
| 700 | 1 | |a Spektor, Tanya M |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 35(2021), 12 vom: 29. Dez., Seite 3534-3541 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:12 |g day:29 |g month:12 |g pages:3534-3541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-021-01354-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 12 |b 29 |c 12 |h 3534-3541 | ||